Who
Katherine Goodrich
Director
Company insider
Files Form 4 as: Director, Tarsus Pharmaceuticals.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $367K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 13 Nov 2024
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $183K2,954 at $62.08 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $183K2,954 at $62.08 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 15 Dec 2025filed 14 Jan 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,233 | filing |
| 15 Dec 2025filed 14 Jan 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,233 at $0.00 | filing |
| 15 Dec 2025filed 14 Jan 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,233 at $0.00 | filing |
| 15 Dec 2025filed 14 Jan 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,233 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,540 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,954 at $0.00 | filing |
| 13 Nov 2024filed 15 Nov 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 13 Nov 2024filed 15 Nov 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,700 at $0.00 | filing |
News
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)TARS · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Katherine Goodrich; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.